Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tabellvi® (Adalimumab) in Chinese Adult Subjects With Moderate to Severe Active Crohn's Disease
NCT07663526Phase 4Recruiting
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 4 trial of adalimumab in Crohn's disease, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Sep 2026; status: recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07663526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663526.